Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed May 14, 2024 · 10-Q · 44 days after period end · 0001410578-24-000820
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$3.40M | -$5.06M | -$5.36M | -$6.66M |
| EPS Diluted | -$0.75 | -$0.14 | -$0.15 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end
